Hester Biosciences Intrinsic Value
Hester Biosciences intrinsic value. Hester Biosciences (HESTERBIO) median intrinsic value is ₹965.93 from 10 valuation models (range ₹706–₹2107), vs current price ₹2352.10 — -58.9% downside (Trading Above Calculated Value), margin of safety -100.0%. Analyse Hester Biosciences ownership pattern to track promoter, FII and institutional holdings.
HESTERBIO Valuation Methods Summary — DCF, Graham Number & P/E
Hester Biosciences intrinsic value across 10 models vs current price ₹2352.10 — upside/downside and value range per method. For current market price and key ratios, visit HESTERBIO screener.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹2106.72 | ₹1685.38 - ₹2528.06 | -10.4% | EPS: ₹95.76, Sector P/E: 22x |
| Book Value Method | asset | ₹817.78 | ₹736.00 - ₹899.56 | -65.2% | Book Value/Share: ₹408.89, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹906.67 | ₹816.00 - ₹997.34 | -61.5% | Revenue/Share: ₹453.33, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹1644.44 | ₹1480.00 - ₹1808.88 | -30.1% | EBITDA: ₹148.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹965.93 | ₹772.74 - ₹1159.12 | -58.9% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹705.63 | ₹635.07 - ₹776.19 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹1479.49 | ₹1331.54 - ₹1627.44 | -37.1% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹1493.33 | ₹1344.00 - ₹1642.66 | -36.5% | ROE: 22.8%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹817.78 | ₹736.00 - ₹899.56 | -65.2% | EPS: ₹95.76, BVPS: ₹408.89 |
| Dividend Yield Method | dividend | ₹705.63 | ₹635.07 - ₹776.19 | -70.0% | DPS: ₹11.00, Target Yield: 2.5% |
HESTERBIO Intrinsic Value vs Market Price — All Valuation Models
Hester Biosciences fair value range ₹706–₹2107 vs current market price ₹2352.10 across 10 valuation models. Browse HESTERBIO financial statements for revenue, profit, balance sheet and cash flow data.
HESTERBIO Intrinsic Value Analysis — Undervalued or Overvalued?
Hester Biosciences median intrinsic value ₹965.93, current price ₹2352.10 — Trading Above Calculated Value by 58.9%, margin of safety -100.0%.
What is the intrinsic value of HESTERBIO?
Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of Hester Biosciences (HESTERBIO) is ₹965.93 (median value). With the current market price of ₹2352.10, this represents a -58.9% variance from our estimated fair value.
The valuation range spans from ₹705.63 to ₹2106.72, indicating ₹705.63 - ₹2106.72.
Is HESTERBIO undervalued or overvalued?
Based on our multi-method analysis, Hester Biosciences (HESTERBIO) appears to be trading above calculated value by approximately 58.9%.
HESTERBIO Financial Health — Key Ratios vs Industry Benchmarks
Hester Biosciences financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Return on Equity | 22.8% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 33.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.60x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
HESTERBIO Cash Flow Quality — Operating & Free Cash Flow
Hester Biosciences operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹64 Cr | ₹55 Cr | Positive Free Cash Flow | 8/10 |
| March 2025 | ₹65 Cr | ₹55 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹48 Cr | ₹37 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹24 Cr | ₹-15 Cr | Positive Operating Cash Flow | 6/10 |
| March 2022 | ₹9 Cr | ₹-50 Cr | Positive Operating Cash Flow | 6/10 |